Home › Funds › BAKER BROS. ADVISORS LP › TSHA

BAKER BROS. ADVISORS LP position in TSHA

TAYSHA GENE THERAPIES INC · Health Care

BAKER BROS. ADVISORS LP reported holding 4,004,756 shares of TSHA (TAYSHA GENE THERAPIES INC) in its Q2 2026 13F filing — a position valued at US$27.3M, representing 0.14% of its reported portfolio and ranking #47 among its reported holdings. BAKER BROS. ADVISORS LP has disclosed TSHA holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)4.00M sh
Reported value held$27.27M
Portfolio Weight0.14%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How BAKER BROS. ADVISORS LP's TSHA position evolved

BAKER BROS. ADVISORS LP first disclosed a stake in TSHA in Q3 2023 at 2,504,756 shares (US$7.9M). The position peaked in Q2 2026 at 4,004,756 shares, worth US$27.3M. Across 12 filings, BAKER BROS. ADVISORS LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 10 time(s). The most recent filing (Q2 2026) shows 4,004,756 shares valued at US$27.3M. Notable position changes include a 60% increase in Q4 2023 (shares rose 62% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 2.50M $7.92M New
Q4 2023 4.00M $7.09M Add
Q1 2024 4.00M $11.49M Hold
Q2 2024 4.00M $8.97M Hold
Q3 2024 4.00M $8.05M Hold
Q4 2024 4.00M $6.93M Hold
Q1 2025 4.00M $5.57M Hold
Q2 2025 4.00M $9.25M Hold
Q3 2025 4.00M $13.10M Hold
Q4 2025 4.00M $22.03M Hold
Q1 2026 4.00M $17.90M Hold
Q2 2026 4.00M $27.27M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About TSHA and 13F data

TSHA (TAYSHA GENE THERAPIES INC) is a Health Care company. 56 other funds we track also report a position in TSHA — the largest reported positions include Avoro Capital Advisors LLC (US$162.7M), RA CAPITAL MANAGEMENT, L.P. (US$160.4M), Vestal Point Capital, LP (US$132.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding TSHA

All TSHA fund holders →

FAQ

How long has BAKER BROS. ADVISORS LP held TSHA?

BAKER BROS. ADVISORS LP has disclosed TSHA holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is BAKER BROS. ADVISORS LP's current position in TSHA?

As of Q2 2026, BAKER BROS. ADVISORS LP holds 4.00M shares of TSHA (TAYSHA GENE THERAPIES INC), valued at $27.27M, representing 0.14% of its reported portfolio and ranking #47.

Has BAKER BROS. ADVISORS LP been buying or selling TSHA?

In the latest 13F filing (Q2 2026), BAKER BROS. ADVISORS LP held unchanged its position in TSHA. The position peaked in Q2 2026 at 4.00M shares.

Which other funds hold TSHA?

Other major institutional holders of TSHA include Avoro Capital Advisors LLC, RA CAPITAL MANAGEMENT, L.P., Vestal Point Capital, LP, among 56 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.